These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 36430728)

  • 1. Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).
    Cassioli C; Patrussi L; Valitutti S; Baldari CT
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.
    Wu L; Wei Q; Brzostek J; Gascoigne NRJ
    Cell Mol Immunol; 2020 Jun; 17(6):600-612. PubMed ID: 32451454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
    Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
    Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
    Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
    Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
    Fraietta JA; Lacey SF; Orlando EJ; Pruteanu-Malinici I; Gohil M; Lundh S; Boesteanu AC; Wang Y; O'Connor RS; Hwang WT; Pequignot E; Ambrose DE; Zhang C; Wilcox N; Bedoya F; Dorfmeier C; Chen F; Tian L; Parakandi H; Gupta M; Young RM; Johnson FB; Kulikovskaya I; Liu L; Xu J; Kassim SH; Davis MM; Levine BL; Frey NV; Siegel DL; Huang AC; Wherry EJ; Bitter H; Brogdon JL; Porter DL; June CH; Melenhorst JJ
    Nat Med; 2018 May; 24(5):563-571. PubMed ID: 29713085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL.
    Collins MA; Jung IY; Zhao Z; Apodaca K; Kong W; Lundh S; Fraietta JA; Kater AP; Sun C; Wiestner A; Melenhorst JJ
    Cancer Res Commun; 2022 Sep; 2(9):1089-1103. PubMed ID: 36922932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T-Cell Activation at the Immunological Synapse.
    Zang H; Siddiqui M; Gummuluru S; Wong WW; Reinhard BM
    ACS Nano; 2022 Nov; 16(11):18408-18420. PubMed ID: 36282488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
    Oluwole OO; Davila ML
    J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
    Bair SM; Porter DL
    Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.
    Naghizadeh A; Tsao WC; Hyun Cho J; Xu H; Mohamed M; Li D; Xiong W; Metaxas D; Ramos CA; Liu D
    PLoS Comput Biol; 2022 Mar; 18(3):e1009883. PubMed ID: 35303007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
    Fraietta JA; Schwab RD; Maus MV
    Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR".
    Teppert K; Wang X; Anders K; Evaristo C; Lock D; Künkele A
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
    Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Halton E; Lamanna N; Rademaker J; Sadelain M; Brentjens RJ; Park JH
    Mol Ther; 2018 Aug; 26(8):1896-1905. PubMed ID: 29910179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
    Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
    Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
    Tettamanti S; Rotiroti MC; Giordano Attianese GMP; Arcangeli S; Zhang R; Banerjee P; Galletti G; McManus S; Mazza M; Nicolini F; Martinelli G; Ivan C; Veliz Rodriguez T; Barbaglio F; Scarfò L; Ponzoni M; Wierda W; Gandhi V; Keating M; Biondi A; Caligaris-Cappio F; Biagi E; Ghia P; Bertilaccio MTS
    Leuk Lymphoma; 2022 Jul; 63(7):1566-1579. PubMed ID: 35259043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
    Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
    J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in modular control of CAR-T therapy with adapter-mediated CARs.
    McCue AC; Yao Z; Kuhlman B
    Adv Drug Deliv Rev; 2022 Aug; 187():114358. PubMed ID: 35618140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.